Explore more price target data and ratings for Adaptive Biotechnologies Corporation on the Forecasts tab, and track all previous and future analyst recommendations for Adaptive Biotechnologies Corporation in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet…
Q2 saw robust revenue and margin growth, led by MRD clinical and pharma segments, with blood-based and community testing adoption accelerating. Guidance was raised for MRD revenue and clinical volumes, while strategic separation of Immune Medicine and capital restructuring further strengthened the…
Q2 2026 saw 30% revenue growth, strong MRD and clinical testing performance, and a raised FY 2026 MRD revenue outlook. Strategic separation of MRD and IM businesses and robust cash reserves position the company for continued growth and operational focus.Original document: Adaptive Biotechnologies C…
SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation NASDAQ:ADPT, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial resu…
Explore more price target data and ratings for Adaptive Biotechnologies Corporation on the Forecasts tab, and track all previous and future analyst recommendations for Adaptive Biotechnologies Corporation in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet…
